These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18537622)

  • 1. From a dull enzyme to something else: facts and perspectives regarding aldose reductase.
    Del Corso A; Cappiello M; Mura U
    Curr Med Chem; 2008; 15(15):1452-61. PubMed ID: 18537622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.
    Kumar M; Choudhary S; Singh PK; Silakari O
    Future Med Chem; 2020 Jul; 12(14):1327-1358. PubMed ID: 32602375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
    Nencetti S; La Motta C; Rossello A; Sartini S; Nuti E; Ciccone L; Orlandini E
    Bioorg Med Chem; 2017 Jun; 25(12):3068-3076. PubMed ID: 28392277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldose reductase inhibitors: 2013-present.
    Quattrini L; La Motta C
    Expert Opin Ther Pat; 2019 Mar; 29(3):199-213. PubMed ID: 30760060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Aldose Reductase in Polyol Pathway: An Emerging Pharmacological Target in Diabetic Complications and Associated Morbidities.
    Gupta JK
    Curr Pharm Biotechnol; 2024; 25(9):1073-1081. PubMed ID: 37649296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldose Reductase: a cause and a potential target for the treatment of diabetic complications.
    Thakur S; Gupta SK; Ali V; Singh P; Verma M
    Arch Pharm Res; 2021 Jul; 44(7):655-667. PubMed ID: 34279787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors.
    Kumar H; Shah A; Sobhia ME
    J Mol Model; 2012 May; 18(5):1791-9. PubMed ID: 21833829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of aldose reductase activity through S-thiolation by physiological thiols.
    Cappiello M; Amodeo P; Mendez BL; Scaloni A; Vilardo PG; Cecconi I; Dal Monte M; Banditelli S; Talamo F; Micheli V; Giblin FJ; Del Corso A; Mura U
    Chem Biol Interact; 2001 Jan; 130-132(1-3):597-608. PubMed ID: 11306078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin K1 prevents diabetic cataract by inhibiting lens aldose reductase 2 (ALR2) activity.
    Thiagarajan R; Varsha MKNS; Srinivasan V; Ravichandran R; Saraboji K
    Sci Rep; 2019 Oct; 9(1):14684. PubMed ID: 31604989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S; Buyukbingol E
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors.
    Balestri F; Quattrini L; Coviello V; Sartini S; Da Settimo F; Cappiello M; Moschini R; Del Corso A; Mura U; La Motta C
    Cell Chem Biol; 2018 Nov; 25(11):1414-1418.e3. PubMed ID: 30122369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzoxazinone-thiosemicarbazones as antidiabetic leads via aldose reductase inhibition: Synthesis, biological screening and molecular docking study.
    Shehzad MT; Imran A; Njateng GSS; Hameed A; Islam M; Al-Rashida M; Uroos M; Asari A; Shafiq Z; Iqbal J
    Bioorg Chem; 2019 Jun; 87():857-866. PubMed ID: 30551808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.
    Srivastava SK; Ramana KV; Bhatnagar A
    Endocr Rev; 2005 May; 26(3):380-92. PubMed ID: 15814847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
    Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O
    Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and kinetic determinants of aldehyde reduction by aldose reductase.
    Srivastava S; Watowich SJ; Petrash JM; Srivastava SK; Bhatnagar A
    Biochemistry; 1999 Jan; 38(1):42-54. PubMed ID: 9890881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate.
    Vander Jagt DL; Kolb NS; Vander Jagt TJ; Chino J; Martinez FJ; Hunsaker LA; Royer RE
    Biochim Biophys Acta; 1995 Jun; 1249(2):117-26. PubMed ID: 7599164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Search of Differential Inhibitors of Aldose Reductase.
    Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A
    Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach to control the enigmatic activity of aldose reductase.
    Del-Corso A; Balestri F; Di Bugno E; Moschini R; Cappiello M; Sartini S; La-Motta C; Da-Settimo F; Mura U
    PLoS One; 2013; 8(9):e74076. PubMed ID: 24019949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.